Table 3 Summary of three cases of roxadustat-induced hypothyroidism
Author | Year | Age (years)/sex | DM | Chronic kidney disease stage | Thyroid disease at base line | Time to onset | Dosage of roxadustat (mg) | TSH (μU/ml) (0.50–5.00) | F-T4 (ng/dl) (0.90–1.70) | F-T3 (pg/ml) (2.30–4.00) |
|---|---|---|---|---|---|---|---|---|---|---|
Ichii et al. [7] | 2021 | 77/male | N | 5D | Ya | 3 months | 120 | < 0.1 | < 1 | NA |
Tokuyama et al. [8] | 2021 | 85/male | N | 5D | Yb | 1 month | 100 | 0.0038 | 0.7 | 2.0 |
Shi et al. [9] | 2023 | 88/male | Y | 4 | N | 3 months | 100 | 0.032 | 0.32 | 0.93 |
Present case | – | 53/male | Y | 5D | N | > 2 years | 150 | 1.146 | < 0.42 | < 1.5 |